Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study
Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn’s disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD.Methods: We conducted a multicenter cross-sectional survey amon...
Guardado en:
Autores principales: | Lingya Yao, Xiao Zhu, Bule Shao, Rongbei Liu, Zhilun Li, Lexi Wu, Jin Chen, Qian Cao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e2a228815b4e48f8bbc0dae0ec89d22a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of ustekinumab in Crohn’s disease
por: Kotze PG, et al.
Publicado: (2018) -
Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto S, et al.
Publicado: (2018) -
Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease
por: Manrong He, et al.
Publicado: (2021) -
Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
por: Fusun Gediz, et al.
Publicado: (2021) -
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
por: Byron P. Vaughn
Publicado: (2021)